Cellectis SA (CMVLF)
OTHER OTC:CMVLF
CMVLF Stock Chart & Stats
$4.40
-$0.25(-16.67%)
At close: 4:00 PM EST
$4.40
-$0.25(-16.67%)
Day’s Range― - ―
52-Week Range$1.25 - $5.04
Previous CloseN/A
Volume1.60K
Average Volume (3M)6.00
Market Cap
$259.38M
Enterprise Value$332.96M
Total Cash (Recent Filing)$185.47M
Total Debt (Recent Filing)$108.49M
Price to Earnings (P/E)―
Beta-0.38
Next Earnings
Jul 30, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding72,325,455
10 Day Avg. Volume20
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)6.52
Price to Sales (P/S)6.52
P/FCF Ratio-11.22
Enterprise Value/Market Cap1.28
Enterprise Value/Revenue4.89
Enterprise Value/Gross Profit6.20
Enterprise Value/Ebitda-7.41
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.86
Revenue Forecast (FY)$61.01M
Bulls Say, Bears Say
Bulls Say
Proprietary Gene‑editing PlatformCellectis' proprietary gene‑editing platform underpins its allogeneic CAR‑T pipeline and is a durable competitive asset. Platform-level IP enables multiple programs and supports licensing and partnerships, creating scalable upside if clinical proof and regulatory progress materialize.
High Gross Margins On RevenueHistorically high gross margins indicate that collaboration and IP revenues are capital‑light and scalable. As revenues grow, these margins can produce operating leverage quickly, helping the company move toward positive operating income once fixed R&D costs are spread over higher top line.
Partner‑driven Revenue ModelA business model centered on collaborations, licensing and milestone payments provides diversified, non‑product revenue streams that can fund development and extend runway. Partner funding reduces sole reliance on product commercialization timing and offers staged, milestone‑linked cash inflows.
Bears Say
Sustained Cash BurnMaterial negative operating and free cash flow indicate the company is burning cash consistently. This persistent burn increases reliance on external financing or partner payments, risks dilution, and constrains strategic flexibility to invest in trials or manufacturing without securing new funding.
Rising Leverage And Shrinking EquitySignificantly higher leverage alongside a declining shareholders' equity base reduces financial resilience. Elevated debt levels increase refinancing and covenant risk, limit optionality for M&A or capex, and can force suboptimal financing or partnership terms if cash needs persist.
Deep And Persistent Operating LossesVery negative net margins and sustained negative EBIT/EBITDA show a structural mismatch between costs and current revenue. Without clear operating scale or cost realignment, profitability remains distant, keeping dependence on external capital and increasing execution risk for long‑dated clinical programs.
Cellectis SA News
CMVLF FAQ
What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was $1.25 and its highest was $5.04 in the past 12 months.
What is Cellectis SA’s market cap?
Cellectis SA’s market cap is $259.38M.
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s upcoming earnings report date is Jul 30, 2026 which is in 60 days.
How were Cellectis SA’s earnings last quarter?
Cellectis SA released its earnings results on May 11, 2026. The company reported -$0.178 earnings per share for the quarter, beating the consensus estimate of -$0.257 by $0.079.
Is Cellectis SA overvalued?
According to Wall Street analysts Cellectis SA’s price is currently Overvalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate is -0.26.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 72,325,455 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Cellectis SA reported an EPS of -$0.178 in its last earnings report, beating expectations of -$0.257. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cellectis SA?
Currently, no hedge funds are holding shares in CMVLF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
CMVLF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in advancing pivotal clinical trials and maintaining a strong financial position, with ongoing collaborations and upcoming strategic events. However, ongoing arbitration and a decrease in cash reserves posed challenges.View all CMVLF earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.02% Other Institutional Investors
99.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---